4//SEC Filing
Oxtoby Andrew 4
Accession 0000899243-20-006850
CIK 0001631650other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 8:35 PM ET
Size
8.1 KB
Accession
0000899243-20-006850
Insider Transaction Report
Form 4
Oxtoby Andrew
Chief Commercial Officer
Transactions
- Award
Common Stock, $0.0001 par value
2020-02-28+11,250→ 23,250 total - Award
Stock Option (right to buy)
2020-02-28+67,500→ 67,500 totalExercise: $23.81Exp: 2030-02-28→ Common Stock (67,500 underlying)
Footnotes (3)
- [F1]These shares represent restricted stock units ("RSUs") and will be settled in common stock upon vesting. The RSUs vest in three successive, equal, annual installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F2]Includes 12,000 RSUs and will be settled in common stock upon vesting. The RSUs vest in four successive, equal, annual installments measured from January 19, 2019 subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
- [F3]The shares subject to the option will vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from March 1, 2020, subject to the Reporting Person's continued service relationship with the Issuer on each such vesting date.
Documents
Issuer
Aimmune Therapeutics, Inc.
CIK 0001631650
Entity typeother
Related Parties
1- filerCIK 0001765473
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 8:35 PM ET
- Size
- 8.1 KB